Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.61 |
| ▸ | RAB9A | P51151 | 9/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 3/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14804393 | 0.89 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL2245998 | 0.84 | DGAT1 (0.72) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9610048 | 0.84 | DGAT1 (0.72) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL27992491 | 0.83 | NPC1 (0.69) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL739207 | 0.83 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| Bromide SCHEMBL5999618 | 0.82 | DGAT1 (0.69) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| Bromide SCHEMBL5999620 | 0.82 | DGAT1 (0.69) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL15272302 | 0.82 | SMN1; SMN2 (0.51) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL10330356 | 0.81 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL8126280 | 0.81 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720065-A1 | PRMT5 INHIBITORS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-04-08 | — | — | EP | disclosed |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | UCB Biopharma SRL (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-4081296-B1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025106386-A1 | A CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | MERCK SHARP & DOHME LLC (US) | 2025-05-15 | — | — | US | disclosed |
| CN-119431269-A | Method for synthesizing 1,3, 4-oxadiazole compound from 1, 2-dihydrazide compound | 浙江工业大学 | 2025-02-14 | — | — | CN | disclosed |
| WO-2024245412-A1 | PRMT5 INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-12-05 | — | — | WO | disclosed |
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4081296-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | disclosed |
| US-11479546-B2 | Antimalarial hexahydropyrimidine analogues | UCB Biopharma SRL | 2022-10-25 | — | — | US | disclosed |
| US-6046210-A | ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-04 | — | — | US | disclosed |
| US-5972951-A | Tetracyclic spiro compounds, process for their preparation and their use as 5HT1D receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-10-26 | — | — | US | disclosed |
| EP-0917530-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-26 | — | — | EP | disclosed |
| US-5714496-A | TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHERSCLEROSIS | ZENECA LIMITED (GB) | 1998-02-03 | — | — | US | disclosed |
| EP-0656897-B1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LTD (GB) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997043262-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-11-20 | — | — | WO | disclosed |
| EP-0799226-A1 | TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019477-A1 | TETRACYCLIC SPIRO COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-06-27 | — | — | WO | disclosed |
| EP-0656897-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1995-06-14 | — | — | EP | disclosed |
| WO-1994005660-A1 | QUINUCLIDINE DERIVATIVES AS SQUALENE SYNTHASE INHIBITORS | ZENECA LIMITED (GB) | 1994-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479546-B2 | Antimalarial hexahydropyrimidine analogues | G6PD, DPYD, DHODH | NPC1 2639/4885RAB9A 4385/4885SMN1; SMN2 3093/4885 |
| US-20230303517-A1 | DIHYDROCYCLOPENTA-ISOQUINOLINE-SULFONAMIDE DERIVATIVES COMPOUNDS | FCER2, FCGR1A, FCGR2A | NPC1 2106/4885RAB9A 1165/4885SMN1; SMN2 4788/4885 |
| US-12577228-B2 | Dihydrocyclopenta-isoquinoline-sulfonamide derivatives compounds | FCGR2A, FCER2, FCGR1A | NPC1 567/4885RAB9A 1049/4885SMN1; SMN2 4565/4885 |
| US-20250152658-A1 | CYCLIC PEPTIDE FOR TRAPPING INTERLEUKIN-1 BETA | IL1R1, IL1A, IL1B | NPC1 2453/4885RAB9A 484/4885SMN1; SMN2 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.